1 |
Aiken, C. and Chen, C. H. 2005. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol. Med. 11, 31-36.
DOI
|
2 |
Xie, R., Zhang, H., Wang, X. Z., Yang, X. Z., Wu, S. N., Wang, H. G., Shen, P. and Ma, T. H. 2017. The protective effect of betulinic acid (BA) diabetic nephropathy on streptozotocin (STZ)-induced diabetic rats. Food Funct. 8, 299-306.
DOI
|
3 |
Bijland, S., Mancini, S. J. and Salt, I. P. 2013. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin. Sci. 124, 491-507.
DOI
|
4 |
Carling, D. 2017. AMPK signalling in health and disease. Curr. Opin. Cell Biol. 45, 31-37.
DOI
|
5 |
Costa, G., Francisco, V., Lopes, M. C., Cruz, M. T. and Batista, M. T. 2012. Intracellular signaling pathways modulated by phenolic compounds: application for new anti-inflammatory drugs discovery. Curr. Med. Chem. 19, 2876-2900.
DOI
|
6 |
Di Pino, A. and DeFronzo, R. A. 2019. Insulin resistance and atherosclerosis: Implications for insulin-sensitizing agents. Endocr. Rev. 40, 1447-1467.
DOI
|
7 |
Fryer, L. G., Parbu-Patel, A. and Carling, D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232.
DOI
|
8 |
Garcia, D. and Shaw, R. J. 2017. AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance. Mol. Cell. 66, 789-800.
DOI
|
9 |
Habegger, K. M., Hoffman, N. J., Ridenour, C. M., Brozinick, J. T. and Elmendorf, J. S. 2012. AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol. Endocrinology 153, 2130-2141.
DOI
|
10 |
Alkhateeb, A. and Bonen, A. 2010. Thujone, a component of medicinal herbs, rescues palmitate-induced insulin resistance in skeletal muscle. Am. J. Phys. Regul. Integr. Comp. Phys. 299, R804-R812.
DOI
|
11 |
Hu, X., Wang, S., Xu, J., Wang, D. B., Chen, Y. and Yang, G. Z. 2014. Triterpenoid saponins from Stauntonia chinensis ameliorate insulin resistance via the AMP-activated protein kinase and IR/IRS-1/PI3K/Akt pathways in insulin-resistant HepG2 cells. Int. J. Mol. Sci. 15, 10446-10458.
DOI
|
12 |
Gibbs, E. M., Stock, J. L., McCoid, S. C., Stukenbrok, H. A., Pessin, J. E., Stevenson, R. W., Milici, A. J. and McNeish, J. D. 1995. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J. Clin. Invest. 95, 1512-1518.
DOI
|
13 |
Saltiel, A. R. and Kahn, C. R. 2001. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414, 799-806.
DOI
|
14 |
Jung, S. H., Ha, Y. J., Shim, E. K., Choi, S. Y., Jin, J. L., Yun-Choi, H. S. and Lee, J. R. 2007. Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator. Biochem. J. 403, 243-250.
DOI
|
15 |
Kanzaki, M. and Pessin, J. E. 2001. Insulin-stimulated GLUT4 translocation in adipocytes is dependent upon cortical actin remodeling. J. Biol. Chem. 276, 42436-42444.
DOI
|
16 |
Pirart, J. 1977. Diabetes mellitus and its degenerative compilations: a prospective study of 4400 patients observed between 1947 and 1973. Diabet. Metab. 3, 168-172.
|
17 |
Ramachandran, V. and Saravanan, R. 2015. Glucose uptake through translocation and activation of GLUT4 in PI3K/Akt signaling pathway by asiatic acid in diabetic rats. Hum. Exp. Toxicol. 34, 884-893.
DOI
|
18 |
Reaven, G. M. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607.
DOI
|
19 |
Song, T. J., Park, C. H., In, K. R., Kim, J. B., Kim, J. H., Kim, M. and Chang, H. J. 2021 Antidiabetic effects of betulinic acid mediated by the activation of the AMPactivated protein kinase pathway. PLoS One 16, e0249109.
|
20 |
Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J. and White, M. F. 1991. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73-77.
DOI
|
21 |
Shah, S. A., Akhtar, N., Akram, M., Shah, P. A., Saeed, T. and Ahmed, K. 2011. Hypoglycemic and hypolipidemic activity of Scopoletin (coumarin derivative) in streptozotocin induced diabetic rats. J. Med. Plant Res. 5, 5662-5666.
|
22 |
Gheorgheosu, D., Duicu, O., Dehelean, C., Soica, C. and Muntean, D. 2014. Betulinic acid as a potent and complex antitumor phytochemical: a minireview. Anticancer Agents Med. Chem. 14, 936-945.
DOI
|
23 |
Babu, P. V. A., Liu, D. and Gilbert, E. R. 2013. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem. 24, 1777-1789.
DOI
|
24 |
Chiu, H. K., Tsai, E. C. and Juneja, R. 2007. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res. Clin. Pract. 77, 237-244.
DOI
|
25 |
Ding, H., Wu, X., Pan, J., Hu, X., Gong, D. and Zhang, G. 2018. New Insights into the inhibition mechanism of betulinic acid on α-glucosidase. J. Agric. Food Chem. 66, 7065-7075.
DOI
|
26 |
Han, J. H., Zhou, W., Li, W., Tuan, P. Q., Nguyen, M. K., Thuong, P. T., Na, M. and Myung, C. S. 2015. Pentacyclic triterpenoids from Astilbe rivularis that enhance glucose uptake via the activation of Akt and Erk1/2 in C2C12 Myotubes. J. Nat. Prod. 78, 1005-1014.
DOI
|
27 |
Kamei, R., Kadokura, M., Kitagawa, Y., Hazeki, O. and Oikawa, S. 2003. 2'-Benzyloxychalcone derivatives stimulate glucose uptake in 3T3-L1 adipocytes. Life Sci. 73, 2091-2099.
DOI
|
28 |
Rajendran, P., Jaggi, M., Singh, M. K., Mukherjee, R. and Burman, A. C. 2008. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest. New Drugs 26, 25-34.
DOI
|
29 |
Rios, J. L. and Manez, S. 2018. New pharmacological opportunities for betulinic acid. Planta Med. 84, 8-19.
DOI
|
30 |
Shoelson, S. E., Lee, J. and Goldfine, A. B. 2006. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801.
DOI
|
31 |
Yamaguchi, S., Katahira, H., Ozawa, S., Nakamichi, Y., Tanaka, T., Shimoyama, T., Takahashi, K., Yoshimoto, K., Imaizumi, M. O., Nagamatsu, S. and Ishida, H. 2005. Activators of AMP-activated protein kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-L1 adipocytes. Am. J. Physiol. Endoc. 289, E643-E649.
|
32 |
Yamauchi, T., Kamon, J., Minokoshi, Y. A., Ito, Y., Waki, H., Uchisa, S., Yamashita, S., Noda, M., Kita, S., Ueki, K. and Eto, K. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295.
DOI
|
33 |
Zhang, B. B., Zhou, G. and Li, C. 2009. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9, 407-416.
DOI
|
34 |
Zimmet, P., Alberti, K. and Shaw, J. 2001. Global and societal implications of the diabetes epidemic. Nature 414, 782-787.
DOI
|
35 |
Weng, L. P., Smith, W. M., Brown, J. L. and Eng, C. 2001. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum. Mol. Gen. 10, 605-616.
DOI
|